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ABSTRACT
Introduction. The five-year survival rate for patients with glio-
blastoma (GBM) is low at approximately 4.7%. Radiotherapy plus 
concomitant and adjuvant temozolomide (TMZ) remains the stan-
dard of care. The optimal duration of therapy with TMZ is unknown. 
This study sought to evaluate the survival benefit of two years of 
treatment.
Methods.xThis was a retrospective chart review of all patients diag-
nosed with GBM and treated with TMZ for up to two years between 
January 1, 2002 and December 31, 2011. The Kaplan-Meier method 
with log-rank test was used to estimate the progression-free survival 
(PFS) and the overall survival (OS). The results were compared to 
historical controls and data from previous clinical trials of patients 
treated up to one year. 
Results. Data from 56 patients with confirmed GBM were evalu-
ated. The OS probability was 54% (SE = 0.068) at one year, 28.3% 
(SE = 0.064) at two years, 17.8% (SE = 0.059) at three years, and 
4% (SE = 0.041) at five years. Seven patients (12.5%) were treated 
with TMZ for two years. Their median time-to-progression was 28 
months (95% CI = 5.0 - 28.0), and they had an increased survival 
probability at three years compared to other patients (log-rank test 
χ2 (1, N = 56) = 19.2, p < 0.0001).
Conclusions. There may be an advantage for a longer duration of 
TMZ therapy among patients with GBM, but the sample size was too 
small for generalization. A multicenter prospective study is needed to 
identify optimal duration of TMZ therapy. 
Kans J Med 2019;12(3):65-69.
INTRODUCTION
Background and Rationale. Brain tumors account for 2% of all 
cancers, but their share of cancer morbidity and mortality remains 
disproportionate.1 Gliomas account for more than 80% of primary 
central nervous system (CNS) malignancies. Malignant, high-grade 
gliomas are grade III (which include anaplastic astrocytomas, ana-
plastic oligodendrogliomas, and anaplastic oligoastrocytoma), and 
grade IV glioblastomas (GBM). Most malignant gliomas are GBMs. 
The Central Brain Tumor Registry of the United States (CBTRUS) 
reported 311,202 new cases of malignant and benign brain and CNS 
tumors from 2005 to 2009.2 The average annual age-adjusted inci-
dence rates for GBM were 2.53 and 3.98 per 100,000 person-years 
for females and males, respectively. The male to female incidence 
ratio was 1.58, whereas the white to black ratio was 2.06. GBMs con-
stituted 15.8% of all reported tumors and 54% of all gliomas. The 
most prevalent locations of all brain tumors were the frontal lobe 
(25.6%) and the temporal lobe (19.6%). The CBTRUS also reported 
the mortality rate from malignant brain and CNS tumors was 3.48 for 
females and 5.23 for males per 100,000 person-years.
The five-year survival rate for GBM is 4.7%.3 Despite a multidisci-
plinary and aggressive treatment approach, GBM continues to have 
the lowest five-year survival rates among all human cancers.4 The 
median survival time from diagnosis rarely exceeds 12 months, and 
may even be shorter.5,6 Patients who survive for more than 36 months 
are considered long-term survivors.
Treatment of GBM is challenging due to resistant tumor cells, the 
innate fragility of the brain, and the inability of most chemotherapeu-
tic agents to cross the blood-brain barrier.  Historically, the standard 
therapy consisted of surgical resection followed by radiotherapy. 
Early clinical trials of the effectiveness of radiotherapy versus radio-
therapy plus concomitant chemotherapy displayed no statistically 
significant survival benefits of chemotherapy.7 However, more recent 
clinical trials and long-term analyses have identified a specific chemo-
therapeutic agent, temozolomide (TMZ), as conferring a statistically 
significant survival benefit when given concurrently with radiation 
therapy (as opposed to radiotherapy alone).8,9 Following the Phase 
III trial by Stupp et al.,8 the current standard of care treatment for 
newly diagnosed GBM after gross-total resection is based on concur-
rent radiation therapy with concomitant TMZ followed by six cycles 
of adjuvant TMZ, known as the Stupp protocol.
Adverse effects of TMZ include myelosuppression and significant 
thrombocytopenia. However, studies have suggested no significant 
increase in TMZ toxicity with prolonged treatment.10,11 For elderly 
patients diagnosed with GBM, six cycles may be sufficient.12 The 
clinical trials that originally established the benefit of TMZ utilized 
a six cycle (six-month) period of treatment.8 Adjuvant TMZ therapy 
for longer than six cycles may yield superior progression-free results 
and overall survival without TMZ toxicity.12-16 The optimal duration 
of therapy with TMZ remains unknown. 
The objective of this study was to evaluate the survival benefit, 
if any, of a longer treatment duration with TMZ using an intent-to-
treat period of two years, given that all the other treatment guidelines 
have been followed.
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The study protocol was approved by the Institutional Review 
Board at the University of Kansas School of Medicine-Wichita. The 
study design consisted of a retrospective chart review of patients with 
GBM who were treated at a cancer referral center in the Midwest, 
with an intent-to-treat protocol under which patients were to be 
treated for two years of adjuvant therapy with TMZ. The results were 
compared to historical controls and data from previous clinical trials, 
where the patients were treated for up to one year. Electronic medical 
charts were the source of the study data. The registry was searched 
using keywords: brain neoplasm, GBM, and glioblastoma. The results 
were filtered according to diagnosis date so that only those treated 
between January 1, 2002 and December 31, 2011 were selected if 
inclusion and exclusion criteria were met. 
Patients were selected according to the following inclusion cri-
teria: 18 years or older, with a GBM diagnosis, received TMZ as 
first-line chemotherapy, with the intent to treat for two years. All 
eligible patients had surgery with the intent of gross total resection, 
followed by imaging assessment within 24 to 48 hours of surgery, and 
concurrent radiation therapy and TMZ within two to four weeks of 
diagnosis, depending on the need for rehabilitation. The continuous 
variables that were abstracted included age, time to progression, and 
time to death. The categorical variables collected included Karnofsky 
Performance Score (KPS), gender, surgical intervention, external 
pathology report verification, and the use and type of seizure medi-
cations. Survival was calculated as the time from surgical diagnosis 
until death or end of the study period, whichever came first. The date 
of death was registered and verified through hospital records or the 
obituary regardless of the cause. The date of diagnosis, date of pro-
gression, and date of death were compared to calculate time interval 
variables. The outcome of interest was survival.
Anticonvulsant therapy was collected as a possible prognostic 
factor. Information on patients who presented with seizures and who 
were on antiepileptic therapy was collected. For patients who did not 
require it therapeutically, antiepileptic therapy also could be started 
as prophylaxis after brain surgery for about three months. There had 
been some concern that the concomitant use of anti-epileptic medi-
cation like hepatic metabolism inducers, which includes many first 
generation antiepileptic medications, may increase the myelotoxicity 
of chemotherapeutic agents. However, the 2010 European Society for 
Medical Oncology clinical practice guidelines do not agree, specifi-
cally as it pertains to temozolomide.13 Regardless, the potential effect 
modification of treatment efficacy among the treatment cohort was 
evaluated by the use of antiepileptic medication.
Potential confounders included type of surgical resection, inac-
curate pathology report, and demographics. Patients with missing 
data about progression time and survival time were censored in the 
analysis. Censoring was assumed to be independent of likely adverse 
reaction to treatment, patient performance status, or treatment effec-
tiveness. Misclassification bias was addressed by recording whether 
the pathology report was reviewed at an external pathology labora-
tory.
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Statistical Methods. All data were collected in Microsoft Excel 
(version 2007) and analyzed using Statistical Analytics Software 
(SAS) version 9.3. Analysis was conducted to determine if there was 
a relationship between the duration of treatment and long-term sur-
vival of patients with GBMs. All tests were evaluated at a p = 0.05 or 
less level of significance. The overall survival from GBM was defined 
as time from surgical resection until death from all possible causes. 
Patients for whom no definite event status (i.e., death) was ascertain-
able, like those lost to follow-up, were considered censored. Patients 
who were alive also were considered censored and accounted for in 
evaluating patient overall survival duration. 
The Kaplan-Meier method with log-rank test was used to esti-
mate the overall survival (OS) probability distribution of patients 
after treatment. To adjust for potential confounding of overall sur-
vival by patient demographics and clinical characteristics, the Cox 
Proportional Hazards (PH) regression model was used to evaluate 
the relationship between survival and those covariates. Covariates 
that had significant influence in determining survival from GBM were 
assessed using the stepwise method of variable selection. Progres-
sion-free survival (PFS) also was evaluated. The event of interest 
in this respect was progression or recurrence of disease within two 
years of start of treatment. Patients who were lost to follow-up before 
their disease progressed were censored. The Kaplan-Meier method 
with log-rank test was used to estimate the progression-free survival 
distribution of patients after treatment. 
RESULTS
The initial search yielded 211 patients, of which 109 had GBM. 
Since TMZ was not first-line treatment until around 2005, all 
patients before that period who were treated with other agents were 
excluded, resulting in a total of 66 patients. Of the 66 patients, there 
were 25 females and 41 males. The mean age at diagnosis was 60 
years (standard deviation of 12.5). A total of 56 patients were includ-
ed in the analysis because of the lack of survival data on 10 patients. 
Seven patients (12.5%) completed two full years of TMZ (Table 1). 
The median age was 62 years for the whole group (56 patients) and 
64 for the group treated with two years of TMZ. The median Karnof-
sky’s performance score (KPS) was 80 for both groups. 
All the patients in the study were on an intent-to-treat protocol for 
a period of two years, but the median survival time was 13 months (SE 
= 0.068). The two-year survival probability was 28.3% (SE = 0.064) 
and the three-year survival probability was 17.8% (SE = 0.059). At 
five years, the computed survival probability was 4% (SE = 0.041).
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Table 1. Patient characteristics. 
2 Years Treatment, 
n (%)
Total, n 
(%)
Age
20 - 44 2 (28.6) 5 (7.5)
45 - 54 13 (19.7)
55 - 64 2 (28.6) 23 (34.9)
65 - 74 2 (28.6) 18 (27.3)
> 74 1 (14.2) 7 (10.6)
Gender
Male 6 (14.6) 41 (62.1)
Female 1 (4.0) 25 (37.9)
Tumor localization
Hemispherea
Right 5 (71.4) 37 (58.7)
Other 2 (28.6) 26 (41.3)
Lobeb
Frontal 4 (57.2) 26 (39.4)
Temporal 1 (14.2) 21 (31.8)
Other 2 (28.6) 19 (28.8)
Treatment
Tumor resection
Total 5 (71.4) 41 (63.1)
Sub-total 2 (28.6) 20 (30.8)
Biopsy 4 (6.1)
Radiotherapy 7 (100.0) 66 (100.0)
Progression 3 (42.9) 40 (67.8)
External pathology review 5 (71.4) 32 (51.6)
Antiepileptic medications 5 (71.4) 50 (75.8)
Enzyme inducers 3 (60.0) 26 (52)
Non enzyme inducers 2 (40.0) 24 (48)
aThe data on three were missing.
bFor tumors that involved more than one lobe, it was reported according to 
the lobe that was most affected. In addition, there was one tentorial, one intra-
ventricular, one insular, one over the corpus callosum and one with multiple 
masses on the left. They were all grouped with occipital and parietal masses 
under “other”.
The median time to progression for the study group was eight 
months. Patients who were treated with two years of TMZ (Figure 
1) had a statistically significant increase in the likelihood of survival 
compared to those with less than two years of treatment (log-rank 
test χ2 (1, N = 56) = 19.2, p < 0.0001). Their median time to progres-
sion was 28 months. Survival was increased significantly for those 
who had a good KPS compared to fair KPS (log-rank test χ2 (1, N = 
56) = 8.5,  p = 0.0034; Figure 2). Survival was also higher among those 
who had a tumor located in the right cerebral hemisphere, compared 
to those with a tumor in other locations (log-rank test χ2 (1, N = 56) = 
5.5, p = 0.018; Figure 3). Patients who had successful gross resection 
had a better chance of survival than those who had a biopsy, but only 
a marginal increase in overall survival compared to those who had a 
sub-total resection (log-rank test χ2 (2, N = 56) =3.8, p = 0.15). Those 
who progressed had decreased survival compared to those who did 
not have progression in their disease. Gender, location, pathology 
review, and the use and type of anti-convulsive medications appeared 
to have no effect on patient survival. Younger patients aged 19 - 44 
(age groups: 19 - 44, 45 - 54, 55 - 64, 65 - 74, and older than 74 years) 
had a marginal increase in survival, although this was not statistically 
significant (log-rank test χ2 (4, N = 56) = 5.27, p = 0.26; Figure 4). 
Figure 1. Overall survival with number of subjects at risk by treatment duration 
of two years or less of Temozolomide. 
Figure 2. Overall survival with number of subjects at risk by Karnofsky’s Per-
formance Score. 
Figure 3. Overall survival with number of subjects at risk by brain hemisphere 
location of the tumor. 
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Figure 4. Overall survival with number of subjects at risk by age group.
After univariate adjustment, good KPS and the location of the 
tumor in the right hemisphere showed significant effect on survival 
(Table 2). After adjusting for other potential predictors in a multivari-
able analysis, only patients with tumors sited in the right side of the 
brain continued to show any significant benefit with treatment (HR 
= 3.077, 95% CI = 1.159 - 8.172; Table 2). Multivariable analysis also 
indicated that the risk of death due to GBM was reduced for persons 
aged 45 to 54 years compared to those aged 75 years or older (HR 
= 0.161, 95% CI = 0.029 - 0.883; Table 2). The two-year treatment 
group analysis suggested a persistent survival advantage, even after 
adjustment, but due to the small sample size, the precision of the 
effect size was not reliable.
Table 2. Multivariable adjusted analysis. 
Univariate Multivariate
Hazard 
Ratio 95% CI
Hazard 
Ratio 95% CI
Age-groups
(vs. >74)
20 - 44 0.301 0.060 - 1.521 0.407 0.038 - 4.366
45 - 54 0.566 0.190 - 1.683 0.161 0.029 - 0.883
55 - 64 0.853 0.330 - 2.206 0.573 0.123 - 2.676
65 - 74 0.788 0.290 - 2.136 0.529 0.099 - 2.822
Female (vs Male) 1.346 0.724 - 2.502 0.910 0.376 - 2.201
KPS fair (vs good) 3.491 1.394 - 8.746 2.970 0.570 - 15.485
Central 
(vs other region) 0.514 0.234 - 1.132 0.412 0.153 - 1.109
Excision: 
sub-total (vs total) 1.521 0.805 - 2.873 1.168 0.531 - 1.109
Excision: biopsy 
(vs total) 2.380 0.818 - 6.928 0.717 0.099 - 5.917
EIAC* 
(vs non-EIAC) 0.716 0.373 - 1.376 .844 0.356 - 2.001
Pathology review: 
no (vs yes) 0.884 0.482 - 1.623 0.990 0.416 - 2.353
Left hemisphere 
(vs right) 1.989 1.086 - 3.643 3.077 1.159 - 8.172
Location: frontal 
(vs temporal) 1.208 0.575 - 2.538 1.589 0.628 - 4.022
Location: other 
(vs temporal) 1.304 0.589 - 2.886 0.970 0.247 - 3.809
*Enzyme inducing anticonvulsant.
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DISCUSSION
This study suggested an increase in overall survival for patients 
who successfully completed two years of TMZ therapy. As previ-
ously mentioned, the optimal duration of therapy using TMZ has not 
been determined and there are limited data available in the litera-
ture.14 In fact, upon extensive literature review, only six small studies 
have evaluated the efficacy of TMZ for an extended period of treat-
ment.10-12,14,17,18 In a 2007 study published by Hau et al.,10 patients with 
GBM receiving first-line TMZ for a median 13 cycles had a median 
PFS of 14 months. Seiz et al.19 found a statistically significant correla-
tion between the number of adjuvant TMZ cycles and both PFS and 
OS in 59 patients treated with more than six cycles of TMZ. Other 
subsequent studies noted a statistically significant increase in PFS 
and OS for patients treated with more than six cycles of adjuvant 
monthly TMZ.12,14,20 As the side effects of TMZ generally are well-
tolerated, it seemed reasonable to evaluate the outcome of patients 
who were treated for a longer period of time.10,11 Although studies 
have evaluated the long-term efficacy of TMZ for glioblastoma, this 
is one of the first studies that examined treatment duration of two 
years with TMZ.
According to population-based studies, the median age at diag-
nosis of GBM is 64 years.2 This is similar to our study where both 
patients who completed two years of TMZ and the sample as a whole 
had a median age above 60 years. Age subgroup analysis suggested 
survival advantage only for those 45 to 54 years compared to those 
older than 74 years. This is likely related to sample sizes in each 
subgroup, which may not be large enough to make predictive conclu-
sions of differential treatment benefits in these subgroups. Also, our 
patient population exhibited a relatively high KPS, which has been 
associated with longer survival. In fact, all patients who completed 
two years of TMZ had a good KPS score; however, the multivariate 
adjustment suggested no effect of KPS on survival (Table 2). These 
results provide an important insight in potential treatment consider-
ations among patients with GBM and it may be of particular interest 
to evaluate in larger clinical trials whether the longer treatment dura-
tion should be assessed in all GBM patients or only those younger 
than 70 years old with good KPS.
In a 2007 analysis of 55 long-term survivors of GBM by Krex et 
al.,4  several clinical and molecular features were associated with long-
term survival. However, this study failed to include details regarding 
pathology review and treatment regimen. Inadvertent inclusion of 
patients with lower grade gliomas, for instance, could have skewed 
their results toward a more favorable outcome. In contrast, in our 
series, all patients except four had evidence of secondary confir-
mation of the GBM diagnosis, and more than half had the results 
externally reviewed at another center (Table 1).
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Our study was consistent with the CBTRUS data regarding male 
to female ratio (1.64 vs 1.58, respectively), median age, and the most 
prevalent locations being frontal and temporal lobes.2 However, con-
trary to the previously published data, the current study suggested 
that good KPS and total resection were not associated with increased 
survival compared to fair KPS and sub-total resection, after adjust-
ing for other potential covariates. In our series, we also observed a 
longer survival for those patients diagnosed with right-sided GBM 
than those with left-sided GBM. Whether this is simply an artifact 
of this patient cohort is unknown. A potential explanation could be, 
however, that since the left hemisphere is commonly the dominant 
hemisphere and the location of the language center, left-sided GBM 
may result in worse outcomes because of loss of essential functions. 
Limitations. There are several potential limitations to this study. 
First, the sample size was not adequate to allow for generalization. 
However, most studies involving GBM and TMZ have relatively 
small sample sizes. A prospective, multicenter study that can include 
a larger sample size might evaluate the question of duration of TMZ 
therapy better. Secondly, this study was a retrospective chart review 
with some missing data that may have introduced bias to the results. 
For instance, one long-term survivor (81 months) in the successfully 
treated group had no external pathology review. Although a pathology 
review also may have confirmed the GBM diagnosis, there were iso-
lated case reports about very long-term survival with verified GBM, 
and one patient still alive after 21 years.20 Additionally, DNA molecu-
lar data for the patients were not available for this study. Therefore, 
we were not able to compare survival according to O6-methylgua-
nine-DNA methyltransferase (MGMT) promoter methylation 
status, which is predictive of the response to TMZ and a favorable 
prognostic factor in GBM.15,18 More recently, over-expression of the 
Deltrex-1 (DTX1) gene was correlated with increased cell migration 
and invasion, whereas over-expression of SLC7A7 predicts poor PFS 
and OS in patients with GBM.16,21 Additionally, some technology was 
not available for this study. For instance, newer studies about surgi-
cal resection and survival in GBM have evaluated a new technology 
consistent with fluorescence-guided resection. Complete surgical 
resection of the enhancing tumor on early MRI and no fluorescent 
residual tissue can have longer OS compared to those with residual 
fluorescent tissue.22 
In conclusion, this study suggested that there may be a survival 
advantage with a longer duration of TMZ therapy in patients with 
GBM, regardless of age, KPS score, or type of surgical resection. In 
the last five years, there has been an increase in data, which suggested 
a benefit of this strategy on PFS and OS. Our study was one of the 
first studies to evaluate treatment duration of two years with TMZ 
in patients with GBM. While we considered the sample size to be too 
small for generalization, larger prospective studies might evaluate 
the question of duration of TMZ therapy better, particularly if both 
clinical and basic science data are paired.
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